Karim Rihawi 1 , Angela Dalia Ricci 1 , Alessandro Rizzo 1 , Stefano Brocchi 2 , Giovanni Marasco 3 , Luigi Vincenzo Pastore 2 , Fabiola Lorena Rojas Llimpe 1 , Rita Golfieri 2 , Matteo Renzulli 2 , *
07 April 2021
Gastric cancer (GC) represents the fifth most frequently diagnosed cancer worldwide, with a poor prognosis in patients with advanced disease despite many improvements in systemic treatments in the last decade. In fact, GC has shown resistance to several treatment options, and thus, notable efforts have been focused on the research and identification of novel therapeutic targets in this setting. The tumor microenvironment (TME) has emerged as a potential therapeutic target in several malignancies including GC, due to its pivotal role in cancer progression and drug resistance. Therefore, several agents and therapeutic strategies targeting the TME are currently under assessment in both preclinical and clinical studies. The present study provides an overview of available evidence of the inflammatory TME in GC, highlighting different types of tumor-associated cells and implications for future therapeutic strategies.